Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 28NIH 21OTHER 17NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Radiotherapy 214Cisplatin 180Cyclophosphamide 169Doxorubicin 138Vincristine 127Paclitaxel 125Filgrastim 121Etoposide 104Carboplatin 100Methotrexate 83Gemcitabine 82Docetaxel 78Cytarabine 78Gene Expression Profiling 74Fluorouracil 74Prednisone 71Granulocyte Colony-Stimulating Factor 66Dexamethasone 66Leucovorin 62Polymerase Chain Reaction 47Immunohistochemistry 46Microarray Analysis 40Daunorubicin 38Irinotecan 37Ifosfamide 37Temozolomide 35Cetuximab 33Amplified Fragment Length Polymorphism Analysis 33Peripheral Blood Stem Cell Transplantation 32Mercaptopurine 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NETWORK × AZD 6244 × Clear all
NCT02337530 2024-03-21

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Canadian Cancer Trials Group

Phase 2 Completed
62 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01783197 2023-08-04

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

Canadian Cancer Trials Group

Phase 1 Completed
39 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡